Fundz

Keros Therapeutics, Inc. reported raising $3.33 Million in an initial SEC Form D filing, from an offering of $10 Million

PUBLIC · KROSApr 29, 2016$3.3M of $10M raised

Amount Raised

$3.33 Million

$3.33 Million sold, per SEC Form D (first sale Apr 29, 2016)

Round Type

Seed

LexingtonBiotechnology

Quick answer

Keros Therapeutics, Inc. raised $3.33 Million in a Seed round, dated April 29, 2016. Keros Therapeutics, Inc. is based in Lexington, South Carolina, United States.

How much did Keros Therapeutics, Inc. raise?
Keros Therapeutics, Inc. raised $3.33 Million in a Seed round on April 29, 2016.
What does Keros Therapeutics, Inc. do?
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß..
Where is Keros Therapeutics, Inc. based and how big is it?
Keros Therapeutics, Inc. is based in Lexington, South Carolina, United States.
Who are the decision-makers at Keros Therapeutics, Inc?
Fundz holds 1 contact at Keros Therapeutics, Inc., including the Director Head of Medical Writing. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Keros Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Genetesis raised $350K (Seed) on June 13, 2016.
  • Animated Dynamics, Inc. raised $1.7M (Seed) on June 13, 2016.
  • Orpheris, Inc. raised $190 (Pre-Seed) on June 13, 2016.
  • SOFIE Biosciences raised $3.7M (Seed) on June 13, 2016.
  • UVision, Inc. raised $110K (Pre-Seed) on June 10, 2016.
  • ReCor Medical, Inc. raised $10M on June 10, 2016.

Who to call at Keros Therapeutics, Inc., and when

A new round usually means Keros Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Keros Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Keros Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Keros Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Keros Therapeutics, Inc.

Location

99 HAYDEN AVENUE

Lexington, South Carolina, United States

About

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing large and small molecules that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead protein therapeutic product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF. Keros’ second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Keros Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJoanne, Director Head of Medical WritingSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Keros Therapeutics, Inc.'s next move

See what Strategic adds

Keros Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.